Lopinavir/Ritonavir + Famotidine = Unknown or no reaction

Effect on Concentration

Lopinavir/Ritonavir
No change
Applies within class?
No
Famotidine
Unknown
Applies within class?
No

Pharmacologic Effects

Lopinavir/Ritonavir
Effect
N/A
Applies within class?
No
Famotidine
Effect
N/A
Applies within class?
No

Interaction History

N/A

Last Updated 14-Aug-2018

Summary

This information can be extrapolated to include all other H2As.

Sources

Lack of effect of gastric acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir in HIV-infected patients. ^

Study Design

To assess the effect of acid-reducing agents on lopinavir/ritonavir, data from two clinical trials (n = 38 and 190) were pooled. Both trials randomized antiretroviral-naïve, HIV-infected patients to receive lopinavir/ritonavir 400/100 mg twice-daily or 800/200 mg once-daily in combination with stavudine and lamivudine, or tenofovir and emtricitabine. Concurrent administration of gastric acid-reducing agents including antacids of various brand names, proton pump inhibitors (omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole), and H2-receptor antagonists (ranitidine, famotidine, cimetidine, and nizatidine) was reported in both trials. Lopinavir and ritonavir pharmacokinetic parameters were evaluated.

Study Results

Thirty subjects were considered users of acid-reducing agents at the times of pharmacokinetic evaluation. Data were not available at the time of this entry.

Study Conclusions

HIV-infected patients who received gastric acid-reducing agents during administration of lopinavir/ritonavir-based treatment regimens did not appear to have a reduction in lopinavir or ritonavir exposures.

References

Chiu YL, Klein CE, Woodward WC, King KR, Naylor C, Awni W, Brun S. Lack of effect of gastric acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir in hiv-infected patients. Aids Patient Care & Stds. 2007; 4: 247-251.